

AFFIRM-AHF

#AHA20



AMERICAN
COLLEGE *of*
CARDIOLOGY®

Trial Description: Patients hospitalized with acute heart failure with LVEF <50% and iron deficiency were randomized to intravenous ferric carboxymaltose with dosing based on weight and hemoglobin levels vs. placebo.

RESULTS

- Primary outcome was composite of total heart failure hospitalizations and cardiovascular death within 52 weeks: ferric carboxymaltose vs. placebo: 52.5% vs. 67.6% ($p = 0.059$)
- Secondary outcome of cardiovascular death: 13.8% vs. 14.2% ($p = 0.89$)
- Total heart failure hospitalizations: 48.9% vs. 53.5% ($p = 0.013$)

CONCLUSIONS

- In patients with acute heart failure and iron deficiency, intravenous ferric carboxymaltose reduced the risk of heart failure hospitalizations with no significant effect on risk of cardiovascular death
- Treatment with ferric carboxymaltose was safe and well tolerated

Ponikowski P, et al. Lancet 2020;Nov 13:[Epub].

